Combined assessment of thrombotic and haemorrhagic risk in acute medical patients

Thrombosis and Haemostasis

Volumn 115, Issue 2, 2016, Pages 392-398

  La Regina, Micaela ^a   Orlandini, Francesco ^a   Marchini, Francesca ^a   Marinaro, Alessia ^a   Bonacci, Rosanna ^a   Bonanni, Paola ^a   Corsini, Francesca ^a   Ceraudo, Anna Maria ^a   Pacetti, Edoarda ^a   Scuotri, Lucia ^a   Costabile, Davide ^b   Dentali, Francesco ^c  

^a Ligurian East Hospital   (Italy)

^b Logness Srl   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Anticoagulants; Haemorrhage; Internal medicine; Prophylaxis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGE; AGED; ARTICLE; ASSESSMENT OF HUMANS; BLEEDING; CAUSE OF DEATH; CENTRAL VENOUS CATHETER; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENDER; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; PRIORITY JOURNAL; PROPHYLAXIS; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; THROMBOSIS; VERY ELDERLY; CARDIOLOGY; CHEMISTRY; HEMORRHAGE; MULTIVARIATE ANALYSIS; PROCEDURES; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CARDIOLOGY; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84957589072     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-12-1050     Document Type: Article

References (17)

1. Tapson VF, et al.; NABOR Steering Committee. Antithrombotic Therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005; 165: 1458–1464.
2. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203–205.
3. Anderson FA Jr, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933–938.
4. Baglin TP, et al. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol 1997; 50: 609–610.
5. Samama MM, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in medical patients with enoxaparin study group. N Engl J Med 1999; 341: 793–800.
6. Leizorovicz A, et al.; PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874–879.
7. Cohen AT, et al.; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo-controlled trial. Br Med J 2006; 332: 325–329.
8. Dentali F, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146: 278–288.
9. Barbar S, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8: 2450–2457.
10. Decousus H, et al.; IMPROVE Investigators.IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139: 69–79.
11. CG92 Venous thromboembolism - reducing the risk: NICE guideline. February 16, 2010. Available at: https://http://www.nic.org.uk/guidance/cg92.
12. Kahn SR, et al. Prevention of VTE in Nonsurgical Patients. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl): e195S–e226S.
13. Cohen AT, et al.; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study (published erratum appears in Lancet 2008; 371: 1914). Lancet 2008; 371: 387–394.
14. Tapson VF, et al.; IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007; 132: 936–945.
15. Marcucci M, et al.; REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Investigators. Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Intern Emerg Med 2013; 8: 509–520.
16. Nieto JA, et al.; ROCamacho Igators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients. A retrospective multicentre study. Eur J Intern Med 2014; 25: 717–723.
17. Nendaz M, et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thromb Haemost 2014; 111: 531–538.